Abbott Laboratories (ABT)
Abbott Laboratories: It's No Longer A Buy For Now
Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter. Abbott Laboratories maintains a fortress-like balance sheet.
Why Abbott Laboratories Stock Was a Winner on Wednesday
Investors bumped its shares higher following a decent, if unspectacular, earnings report.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
ABT delivers a strong underlying base business performance in the third quarter of 2024.
Committee Stocks on the Move: Interactive Brokers, Abbott Labs and Rio Tinto
The Investment Committee discuss some of their stocks on the move.
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q3 2024 Results Conference Call October 16, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Matt Miksic - Barclays Danielle Antalffy - UBS Operator Good day, and thank you for standing by. Welcome to Abbott's Third Quarter 2024 Earnings Conference Call.
Abbott Laboratories Raises Its Outlook on Strong Medical Device Sales
Abbott Laboratories (ABT) shares rose Wednesday, after the drug and healthcare products maker reported better-than-expected quarterly results and raised the midpoint of its profit outlook on strong demand for its medical devices.
Quarterly Earnings Reports Summary
This morning, we see a new print on international trade as well as further articulation on Q3 earnings, particularly in banking/finance and Big Pharma. Pre-market futures are slightly up at this hour: the Dow +22 points, the S&P 500 +1 and the Nasdaq +5 points.
Abbott Q3: Strong Growth In Medical Device And Pharma
I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals, leading to raised full-year EPS guidance. Despite ongoing NEC baby formula lawsuits, the financial impact is marginal, representing only 0.02% of total revenue.
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
Abbott (ABT) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.14 per share a year ago.
Abbott's Growth and Dividends Make It a Smart Portfolio Pick
There are many reasons to own Abbott Laboratories NYSE: ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.
